摘要:
This invention relates to compositions comprising an agent, which inhibits signaling via the FcgammaRIIB receptor and an agent which stimulates or enhances signaling via an FcgammaRI receptor, an FcgammaRIIa receptor, an FcgammaRIII receptor, or a combination thereof. The invention also provides for the use of such compositions in stimulating or enhancing an immune response, and in treating, suppressing, or preventing cancer in a subject.
摘要:
The present invention relates to methods for promoting somatic embryogenesis from a plant cell, tissue, organ, callus or cell culture, by overexpressing a PGA37 gene in the tissue or organ. In one embodiment, such overexpression can be used as a silent selectable marker for transgenic plants. In another embodiment, such expression can be used to confer apomixis to a plant. In another embodiment, such overexpression can be used to create haploid plants, which can be used to produce dihaploid plants.
摘要:
The present invention provides a method for identifying an agent to be tested for an ability to treat a psychotic disorder in a patient in need of such treatment. The invention provides a method for screening candidate drugs for anti-psychotic drug activity, preferably atypical anti-psychotic activity, comprising contacting cells or tissues with a candidate drug, determining levels of phosphorylation of the intracellular signaling proteins, DARPP-32, ERK1, ERK2 and CREB, in said cells or tissues and determining the pattern of the levels of phosphorylation of the proteins. The pattern of the levels of phosphorylation of DARPP-32, ERK1, ERK2 and CREB is, in certain embodiments, compared with the pattern of the levels of phosphorylation of DARPP-32, ERK1, ERK2 and CREB in the presence of an atypical anti-psychotic drug.